AI
UnitedHealth Pours $1.5B Into AI, Expects $3B Back in 18 Months
UnitedHealth's Q1 AI math: spend $1.5B, scale Optum Real to 2.5B transactions, book 2-to-1 back inside 18 months.
ai
Latest — Page 15
AI
Utah Cleared Doctronic for AI Prescription Refills. Who's Next?
A couple of months ago, Utah allowed startup Doctronic to use AI to refill prescriptions.
Legal
Sued Over Prediction Markets, Coinbase and Gemini Push Back
New York's Office of the Attorney General sued Coinbase and Gemini in state court Tuesday, charging both companies with operating illegal, unlicensed…
Legal
PACE Act Cuts 40-State License Requirement for Payment Fintechs
Two House members introduced the Payments Access and Consumer Efficiency (PACE) Act on April 21, giving nonbank payment service providers a federal path to…
FDA
Roche Fenebrutinib Clears Phase 3, Carries 8-to-1 Death Gap
Roche's fenebrutinib posted eight deaths against Aubagio's one across its two phase 3 relapsing MS trials, and at the American Academy of Neurology Annual…
FDA
Replimune cuts 224 jobs after FDA's second RP1 rejection
FDA rejected Replimune's RP1 for advanced melanoma a second time, and 224 Massachusetts employees are now paying for it.
FDA
NC Biotech Gathers CAR-T Crowd at UNC Friday After $7B Kelonia Deal
CAR-T makers hit UNC Chapel Hill Friday, five days after Lilly's $7B Kelonia bet turned the CMC question into the deal question.
fda
FDA
Roche MS Pill Doubles Relapse-Free Time, Flags Liver Risk
Roche's multiple sclerosis pill more than doubled patients' relapse-free intervals compared with Sanofi's marketed MS pill Aubagio, according to data…
AI
Questioned by 2 Lawmakers, JetBlue Faces AI Pricing Probe
Two lawmakers sent JetBlue a formal letter on April 20 demanding answers about whether the airline uses AI and customer data to set prices.
FDA
Carvykti shows promise in all 20 smoldering myeloma patients
All 20 patients with high-risk smoldering multiple myeloma showed results with Carvykti in a Dana-Farber Cancer Institute study, researchers reported.
FDA
Failed: Merck's Welireg Combo in First-Line Kidney Cancer
Merck's combination of Welireg and Keytruda failed to deliver a significant improvement in newly diagnosed patients with advanced kidney cancer, the company…
Legal
Sued for Price-Fixing, Amazon Faces California AG at July 23 Hearing
California Attorney General Rob Bonta sued Amazon, alleging the company ran a years-long price-fixing scheme that lifted consumer prices across rival retail…
Legal
Ordered to Pay $35K, Key Tronic Executives Doctored Inventory Records
The SEC charged Key Tronic, a contract manufacturer of computer components and medical devices, along with two executives: Brett Larsen, the company's CFO…
AI
Grilled by Florida Over Mass Shooting, OpenAI Defends ChatGPT
Florida's Uthmeier is threatening personal accountability for OpenAI leadership if investigators find the company knew ChatGPT was being used to plan a mass…
FDA
Novartis Cuts 2 Late-Stage Programs on Inferior Efficacy Data
Novartis axed two late-stage programs targeting cancer-related blood clots after observing "inferior efficacy" in a clinical trial, the company confirmed.
